Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating MutationBenjamin P Brown, Yun-Kai Zhang, David Westover, et al.
Plos One|November 17, 2025
Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samplesWenshu Li, Jeffrey A Leibowitz, Shuoguo Wang, et al.
JCO Precision Oncology|October 20, 2022
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesHatim Husain, Dean C Pavlick, Bernard J Fendler, et al.
The Lancet. Digital Health|May 26, 2023
Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysisSmruthy Sivakumar, Jessica K Lee, Jay A Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
The Oncologist|March 12, 2017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> AlterationJulia A Elvin, Laurie M Gay, Rita Ort, et al.
Cancer|June 6, 2017
Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapySiraj M Ali, Ming Yao, Jicheng Yao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2018
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase InhibitorsAlexa B Schrock, Viola W Zhu, Wen-Son Hsieh, et al.
BJU International|January 28, 2020
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertionsRussell W Madison, Sumati V Gupta, Yasir Y Elamin, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating MutationBenjamin P Brown, Yun-Kai Zhang, David Westover, et al.
Plos One|November 17, 2025
Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samplesWenshu Li, Jeffrey A Leibowitz, Shuoguo Wang, et al.
JCO Precision Oncology|October 20, 2022
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesHatim Husain, Dean C Pavlick, Bernard J Fendler, et al.
The Lancet. Digital Health|May 26, 2023
Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysisSmruthy Sivakumar, Jessica K Lee, Jay A Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
The Oncologist|March 12, 2017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> AlterationJulia A Elvin, Laurie M Gay, Rita Ort, et al.
Cancer|June 6, 2017
Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapySiraj M Ali, Ming Yao, Jicheng Yao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2018
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase InhibitorsAlexa B Schrock, Viola W Zhu, Wen-Son Hsieh, et al.
BJU International|January 28, 2020
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertionsRussell W Madison, Sumati V Gupta, Yasir Y Elamin, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
Pageof 13